Literature DB >> 19105971

A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy.

Maarja Mäe1, Samir El Andaloussi, Per Lundin, Nikita Oskolkov, Henrik J Johansson, Peter Guterstam, Ulo Langel.   

Abstract

Aberrations in splicing patterns play a significant role in several diseases, and splice correction, together with other forms of gene regulation, is consequently an emerging therapeutic target. In order to achieve successful oligonucleotide transfection, efficient delivery vectors are generally necessary. In this study we present one such vector, the chemically modified cell-penetrating peptide (CPP) TP10, for efficient delivery of a splice-correcting 2'-OMe RNA oligonucleotide. Utilizing a functional splice correction assay, we assessed the transfection efficiency of non-covalent complexes of oligonucleotides and stearylated or cysteamidated CPPs. Stearylation of the CPPs Arg9 and penetratin, as well as cysteamidation of MPG and TP10, did not improve transfection, whereas the presence of an N-terminal stearyl group on TP10 improved delivery efficiency remarkably compared to the unmodified peptide. The splice correction levels observed with stearyl-TP10 are in fact in parity with the effects seen with the commercially available transfection agent Lipofectamine 2000. However, the inherent toxicity associated with cationic lipid-based transfections can be completely eliminated when using the stearylated TP10, making this vector highly promising for non-covalent delivery of negatively charged oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19105971     DOI: 10.1016/j.jconrel.2008.11.025

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  38 in total

Review 1.  Cell penetrating peptides: overview and applications to the delivery of oligonucleotides.

Authors:  F Said Hassane; A F Saleh; R Abes; M J Gait; Bernard Lebleu
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

2.  Cell-Penetrating Peptides Delivering siRNAs: An Overview.

Authors:  Luca Falato; Maxime Gestin; Ülo Langel
Journal:  Methods Mol Biol       Date:  2021

3.  A peptide-based vector for efficient gene transfer in vitro and in vivo.

Authors:  Taavi Lehto; Oscar E Simonson; Imre Mäger; Kariem Ezzat; Helena Sork; Dana-Maria Copolovici; Joana R Viola; Eman M Zaghloul; Per Lundin; Pedro M D Moreno; Maarja Mäe; Nikita Oskolkov; Julia Suhorutšenko; C I Edvard Smith; Samir E L Andaloussi
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

4.  A high-throughput screening assay for the functional delivery of splice-switching oligonucleotides in human melanoma cells.

Authors:  John M Dean; Robert K DeLong
Journal:  Methods Mol Biol       Date:  2015

Review 5.  A role for peptides in overcoming endosomal entrapment in siRNA delivery - A focus on melittin.

Authors:  Kirk K Hou; Hua Pan; Paul H Schlesinger; Samuel A Wickline
Journal:  Biotechnol Adv       Date:  2015-05-27       Impact factor: 14.227

Review 6.  Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery.

Authors:  Helerin Margus; Kärt Padari; Margus Pooga
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

7.  Lipo-oligoarginines as effective delivery vectors to promote cellular uptake.

Authors:  Jae Sam Lee; Ching-Hsuan Tung
Journal:  Mol Biosyst       Date:  2010-08-09

8.  Enhanced cellular uptake and metabolic stability of lipo-oligoarginine peptides.

Authors:  Jae Sam Lee; Ching-Hsuan Tung
Journal:  Biopolymers       Date:  2011-05-31       Impact factor: 2.505

9.  Development of cholesteryl peptide micelles for siRNA delivery.

Authors:  Bin Qin; Zhijin Chen; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2013-08-19       Impact factor: 9.776

10.  Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP.

Authors:  Oskar Gustafsson; Julia Rädler; Samantha Roudi; Tõnis Lehto; Mattias Hällbrink; Taavi Lehto; Dhanu Gupta; Samir El Andaloussi; Joel Z Nordin
Journal:  Pharmaceutics       Date:  2021-06-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.